Background. Antiretrovirals (ARVs) affect bone density and turnover, but their effect on risk of fractures and osteonecrosis of the femoral head is less understood. We investigated if exposure to ARVs increases the risk of both bone outcomes.
Fractures and osteonecrosis of the femoral head have emerged as important manifestations of bone disease during treated human immunodeficiency virus (HIV) infection. According to population-based studies [1] [2] [3] , HIV-positive persons have a 1.5-3.0 greater risk of fractures than the general population. Osteonecrosis of the femoral head, although a rare bone disease, also disproportionally affects HIV-positive persons. In the setting of HIV infection, it was estimated that osteonecrosis has a 100-fold excess risk when compared to the general population [4] .
Initiation of antiretroviral therapy (ART) is associated with reduction in bone mineral density [5] [6] [7] and increases levels of markers of bone turnover [5, 8] . The loss of bone mineral density following ART initiation is comparable in magnitude to that occurring during the perimenopausal period [9] and treatment with corticosteroids [10] . Changes in bone mineral density and turnover are observed irrespective of ART regimen, but tenofovir disoproxil fumarate (TDF)-containing regimens causes greater bone loss [6, 11] whereas integrase inhibitor-based regimens may cause less bone loss [7] . However, the direct clinical consequences of this are yet to be determined because changes in bone mineral density are not perfect predictors of fracture risk [12] , and the effect of ART exposure on the risk of fractures and osteonecrosis remain poorly understood. In a large HIV cohort, we set out to study the association of exposure to antiretroviral drugs with incident fractures and osteonecrosis of the femoral head and to determine factors independently associated with these two bone outcomes.
METHODS
The EuroSIDA study, a multinational prospective cohort of 20 854 HIV-positive persons from across Europe, Argentina, and Israel, has been documented in detail elsewhere [13] . Briefly, detailed information on clinical, virological, and immunological parameters has been collected every 6 months with accurate recording of dates of AIDS-defining illnesses and serious non-AIDS-defining events, defined as cardiovascular disease, endstage hepatic/renal disease, non-AIDS-defining malignancies, and pancreatitis [14] . Data quality is assured by yearly monitoring visits to participating clinics and hospitals, when source documentation and dates of reported clinical events are crosschecked. In this study, we included persons aged >16 year with baseline data on CD4 counts and viral loads with prospective follow up. Baseline was defined as 1/1/2004, when routine prospective collection of data on fractures and osteonecrosis of the femoral head was initiated in EuroSIDA. Data on fractures and osteonecrosis were reported in follow-up forms by the attending physician. Participating sites reporting no cases of fractures or osteonecrosis or with less than 100 person-years of follow-up (PYFU) were excluded due to concerns about underreporting and data quality on bone outcomes.
Poisson regression using generalized estimating equations was used to identify clinical, laboratory, and demographic factors associated with fractures and osteonecrosis of the femoral head. More than one outcome per person was included accounting for correlation between and within included persons. Factors adjusted for were chosen on the basis of their epidemiological importance and biological plausibility and included baseline and time-updated variables, as defined in a previous report [14] . To avoid model overfitting, factors with marginal associations (P < .1) in univariate analyses were included in multivariate models. Nadir, baseline, and current CD4 counts, baseline and current viral load, as well as age, were all investigated as categorical and continuous variables with different transformations to identify the best-fitting model. Clinical events were modeled as time-updated covariates in different ways to identify the best-fitting model, including nonmalignant AIDS events, AIDS-defining cancer, non-AIDS-defining malignancies and cardiovascular disease, and each of these as a recent event, that is, occurring within the last 12 months prior to the diagnosis of fracture or osteonecrosis.
Each antiretroviral was included in the best-fitting multivariate model to assess the effect of its exposure on the subsequent risk of fractures or osteonecrosis of the femoral head. Exposure to each antiretroviral was included as ever (yes/no), current (yes/no), and cumulative exposure. Antiretrovirals tested were zidovudine, didanosine, stavudine, lamivudine, emtricitabine, TDF, abacavir, nevirapine, efavirenz, saquinavir, ritonavir, lopinavir, indinavir, nelfinavir, atazanavir, ritonavir boosted lopinavir, and any other boosted protease inhibitors (grouped into one category). Antiretrovirals that remained independently associated with risk for fractures or osteonecrosis were subsequently mutually adjusted for. It was not possible to assess other antiretrovirals such as integrase inhibitors owing to their short cumulative exposure among EuroSIDA participants.
We carried out secondary analyses restricted to osteoporotic fractures, grouped as fractures of the spine, arm, wrist, and hip. Similar to other cohort studies without data on bone mineral density [15, 16] , our assumption was that fractures in these locations were more likely to be osteoporotic. Previous investigations reported an increased fracture risk among persons receiving TDF and boosted protease inhibitors concomitantly [16] . Therefore, we also investigated incidence rates of fractures according to 3 categories of current ART use: (1) current use of TDF but not boosted protease inhibitor; (2) current use of boosted protease inhibitor but not TDF; and (3) concomitant use of TDF and boosted protease inhibitor. Using category 3 as the comparator, we compared the incidence rate ratios of fractures across these 3 categories in models adjusted for demographics, HIV-specific variables and comorbidities.
Finally, patients presenting with severe Pneumocystis pneumonia are likely to be treated with adjuvant corticosteroids. We examined the association between past history of Pneumocystis pneumonia, as a proxy of corticosteroid exposure, and subsequent risk for fractures and osteonecrosis.
RESULTS
Of 20 854 EuroSIDA participants, 14 917 had prospective follow-up after baseline and were eligible for inclusion. An additional 1,902 participants were excluded due to missing CD4 counts and/or viral load at baseline. And 1,195 persons were excluded from sites with less than 100 PYFU or where no fractures or osteonecrosis were reported. Thus, 11 820 participants were eligible for final inclusion in the analyses (Supplemental Figure 1) .
The odds of being excluded because of missing CD4 and viral load were higher in all HIV exposure groups compared to men who have sex with men (MSM), in all regions of Europe (except North) compared to South, and in those with hepatitis C virus (HCV) infection at baseline. The odds of being excluded due to missing CD4 and viral load were lower in those who had started ART, were older, had a later date of recruitment to EuroSIDA, and in those with a higher nadir CD4 count. Participants excluded from small study sites or with no reported events were more likely to be older, female, nonwhite, non-MSM, and to be on ART and have a later date of enrolment to EuroSIDA. Table 1 summarizes participant characteristics at the time of diagnosis of fractures or osteonecrosis and at last visit for those without either outcome. There was a higher proportion of fractures and osteonecrosis among intravenous (IV) drug users and HCVcoinfected persons. Persons with a bone outcome tended to have a lower current CD4 count than those without an event. Persons with osteonecrosis had significantly higher levels of triglycerides. There were no differences between participants with and without a bone outcome in terms of chronic kidney disease, estimated glomerular filtration rate (eGFR), and vitamin D levels (Table 1) .
Among 11 820 included participants during 86 118 PYFU, 496 persons had 619 incident fractures (incidence rate [IR]/1000 Figure 1) . Considering fractures with a known site, the most frequent were fractures of the leg, followed by arm, ribs, and foot. In sum, 132 fractures (21.3%) were classified as osteoporotic (Supplemental Figure 2) . At last visit, participants with osteoporotic fractures were more likely to be older, have sexually acquired HIV, and to come from North Europe compared to participants with other fractures but had otherwise similar demographic and clinical characteristics (Supplemental Table 1 ). Information regarding fracture site could not be ascertained for 202 fractures (32.6%). Participants with fractures of unknown sites were more likely to be female, to be ART naive at study entry, have a prior AIDS diagnosis, and have a higher current CD4 count when compared to participants with known fracture sites.
In analyses stratified by time-updated CD4 count, the crude incidence of fractures decreased as CD4 counts increased (P < .0001). On the other hand, the incidence of osteonecrosis did not vary significantly across different CD4 count strata (P = .055).
Univariate and multivariate associations between covariates and risk for fractures and osteonecrosis are detailed in Supplemental Tables 2 and 3 . After adjustment, an increased risk of incident fractures was independently associated with older age, lower BMI, IV drug use, HCV coinfection, prior fracture, prior osteonecrosis of the femoral head, a recent non-AIDS-defining malignancy and recent cardiovascular disease (Figure 1 ). Another independent predictor of fractures was origin, with participants from Northern and Central Europe at significantly increased risk (Supplemental Table 2 ). Race other than white and a higher current CD4 count were associated with lower fracture risk (Figure 1 ). Findings were not substantially different between men and women (data not shown).
With respect to osteonecrosis of the femoral head, a prior history of osteonecrosis, fractures and AIDS-defining illnesses (both opportunistic infections and AIDS-defining cancers) was independently associated with increased risk (Figure 1) . Race other than white and a higher baseline CD4 count were independently associated with a lower risk for osteonecrosis ( Figure 1) .
In univariate analyses, ever, current and cumulative exposure to TDF was associated with increased fracture risk. Crude incidence rates are depicted in Figure 2 . Whether modeled as ever, current, or cumulative, no association between exposure to any of the other investigated antiretrovirals and fracture risk was observed (data not shown). After adjustment (Figure 3) , Figure 1 . Factors independently associated with fractures and osteonecrosis of the femoral head. Models adjusted for depicted covariates plus calendar year and region. Only covariates significant (P < .1) in univariate analyses were included in multivariate models to avoid overfitting. persons who had ever used TDF (adjusted incidence rate ratio [aIRR], 95% CI: 1.40, 1.15-1.70, P = .0008) or who were currently receiving TDF (aIRR 1.25, 1.05-1.49, P = .012) had a significantly increased incidence of fractures. The association of fracture risk with cumulative exposure to TDF did not retain statistical significance after adjustment (aIRR 1.08, 0.94-1.25, per 5 years of additional exposure, P = .27). In analyses restricted to osteoporotic fractures, no significant association was seen with ever, current, or cumulative exposure to TDF (Figure 3) .
In adjusted analyses to investigate incidence rate ratios of fractures for categories of current ART use stratified according to TDF and boosted protease inhibitor, we found no difference in fracture risk in those receiving TDF but not boosted protease inhibitor (aIRR, 95% CI: 0.91, 0.71-1.18, P = .49) and in those receiving boosted protease inhibitor but not TDF (aIRR, 95% CI: 0.87, 0.65-1.03, P = .09) when compared to persons simultaneously receiving TDF and boosted protease inhibitor.
After adjustment, persons who had ever used didanosine, indinavir, saquinavir, ritonavir boosted lopinavir, or TDF, had increased incidence rates of osteonecrosis of the femoral head (Figure 4) , although the confidence intervals were quite wide reflecting the lower number of outcomes. However, when these antiretrovirals were mutually adjusted for, there was no significant relationship between exposure to any of them and osteonecrosis risk (Figure 4) , although all of them were associated with a nonsignificant increased risk. There was no association between cumulative exposure to any of these antiretrovirals and osteonecrosis. Current use of ritonavir boosted lopinavir or TDF was not associated with an increased incidence of osteonecrosis of the femoral head. There were not sufficient data to examine current exposure to didanosine, indinavir, or saquinavir as these antiretrovirals are no longer commonly used. Whether assessed as ever, current, or cumulative, exposure to none of the other investigated antiretrovirals was associated with osteonecrosis of the femoral head.
Pneumocystis pneumonia was associated with both bone outcomes in univariate analyses (IRR, 95% CI: 1.35, 1.02-1.79, P = .039, for fractures; and 2.61, 1.41-4.83, P = .0022, for osteonecrosis); this association, however, was no longer significant after adjustment (adjusted IRR, 95% CI: 0.99, 0.72-1.36, P = .94, for fractures; and 1.27, 0.63-2.49, P = .51, for osteonecrosis).
DISCUSSION
In a large international HIV cohort involving participants receiving standard of care, we report that fractures and osteonecrosis of the femoral head are common bone outcomes. The risk of fractures and osteonecrosis seems to be determined by combination of host factors, HIV-specific variables and comorbidities. We demonstrated that past and current exposure to TDF, but no other antiretroviral, was independently associated with higher incidence of fractures. Persons who had ever used didanosine, indinavir, saquinavir, ritonavir boosted lopinavir, or TDF, had higher risk of osteonecrosis of the femoral head, but this association was no longer significant after mutual adjustment.
Consistent with previous reports, we found that older age [1, 16] , white race [1, 16] , lower current CD4 count [17, 18] , IV drug use [1, 19] and HCV coinfection [1, 19] were independent predictors of fracture risk. We found that history of prior osteonecrosis, a recent non-AIDS-defining cancer and recent cardiovascular disease were also associated with subsequent risk of fracture. The association with cancer and cardiovascular disease may reflect bone loss caused by comorbidity treatments such as chemotherapy. It is also possible that a shared pathophysiological mechanism may lead to an increased risk of fractures and comorbidities during HIV infection [20] .
Exposure to TDF was linked to an increased risk of fractures in our study. Although smaller studies failed to find this association [15, 17] , our results are in overall agreement with larger and more recent cohort studies [1, 16] . The question as to how TDF directly causes bone loss remains unanswered. Proximal tubular toxicity leading to phosphate wasting and enhanced bone turnover is a possible mechanism [21] . However, proximal tubular renal dysfunction and enhanced bone turnover do not necessarily coexist [22] . In our study, there was no difference in renal function, as measured by eGFR, between those with and without a bone event. This suggests that TDF-associated bone toxicity and nephrotoxicity may be determined by different mechanisms. However, we did not compare proteinuria, glycosuria, and phosphaturia among participants with and without fractures, and it is possible that proximal tubular dysfunction among those receiving TDF may have preceded measurable changes in eGFR.
Of note, we found that past and current exposure to TDF, but not cumulative exposure, was associated with a significantly increased risk of fractures. A possible explanation is the fact that decreases in bone mineral density and increases in markers of bone turnover are steepest in the first one or two years following ART initiation [5, 6, 23] . After a critical initial period, abnormalities in bone metabolism caused by ART may not be progressive [23] . Consistent with this, the risk of fractures was found to be highest during the first 2 years of ART [15] to then continue to increase less steeply. We found an aIRR for fracture risk of 1.08 per 5 years of additional exposure to TDF. Although this was not statistically significant, we cannot exclude the possibility of 8% yearly cumulative risk of fractures with TDF exposure.
The pathophysiology of osteonecrosis of the femoral head is poorly understood [24] , but the primary mechanism is vascular occlusion leading to bone hypoxia and necrosis [25] . Increased inflammation and coagulation, as demonstrated by elevated levels of D-dimer and C-reactive protein, were also linked to osteonecrosis risk [26] . In accordance with other studies, we found that history of ADS-defining conditions and lower CD4 counts [27] [28] [29] are associated with increased risk of osteonecrosis. White race and history of prior fractures and prior osteonecrosis were factors independently associated with incident osteonecrosis. These same factors predicted fracture risk, which may be potentially explained by a common mechanism underlying the excess risk of osteoporosis and osteonecrosis in the setting of HIV infection [30] . However, whereas osteoporotic fractures are the clinical manifestation of low bone mineral density, osteonecrosis has a different pathogenesis involving impaired circulation [25] .
We found past exposure to didanosine, indinavir, saquinavir, ritonavir boosted lopinavir, or TDF to be independently associated with osteonecrosis risk. However, after mutual adjustment, these associations were attenuated and became no longer significant. A possible association between protease inhibitors and osteonecrosis risk was reported in a meta-analysis of casecontrol studies [31] . Our study was more methodologically sound because we had detailed time-updated information on exposure to individual antiretrovirals and performed mutual adjustment. However, we cannot exclude the possibility that ART exposure may have a small effect on osteonecrosis risk. If this was the case, the effect of individual antiretrovirals may have been too weak to be identified concomitantly with other bone-active drugs [32] .
Our study had important limitations. First, we had no data on bone mineral density, and bone events were not centrally adjudicated. Therefore, we could not confirm the osteoporotic nature of fractures. Information on anatomic sites was unavailable for a sizeable proportion of fractures. Magnetic resonance imaging was not systematically performed to diagnose osteonecrosis of the femoral head; the occurrence of bone events was confirmed during monitoring visits only. Second, we had no data on alcohol use and use of corticosteroids, megestrol acetate, or testosterone. Exposure to these drugs has been previously reported in relation to risk of fractures and osteonecrosis [29, 33, 34] . We investigated previous history of Pneumocystis pneumonia as a proxy for corticosteroid exposure and found no significant association in adjusted analyses. Third, ART evolves quickly, and it is unclear whether our findings are generalizable to tenofovir alafenamide (TAF)-or integrase inhibitor-based ART regimens.
To conclude, fractures and osteonecrosis of the femoral head are manifestations of bone disease among HIV positive persons receiving ARV treatment. Host factors, HIV-specific variables and comorbidities contribute to the risk of these bone events. Past and current exposure to TDF, but not cumulative exposure, is independently associated with fracture risk. Our data support cautious use of TDF among HIV-positive persons at fracture risk initiating ART as recommended by current guidelines [35] and expert panels [36] . Individual antiretrovirals are not significantly associated with risk of osteonecrosis of the femoral head after mutual adjustment. However, we could not exclude a small effect of ART exposure on osteonecrosis risk. Larger studies are warranted to clarify this.
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